Entellus Medical, Inc. (NASDAQ:ENTL) VP Timothy B. Petrick sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $20.01, for a total transaction of $40,020.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Timothy B. Petrick also recently made the following trade(s):

  • On Friday, September 22nd, Timothy B. Petrick sold 2,000 shares of Entellus Medical stock. The stock was sold at an average price of $18.00, for a total transaction of $36,000.00.

Entellus Medical, Inc. (ENTL) opened at 20.30 on Monday. The company’s 50-day moving average is $18.04 and its 200 day moving average is $18.04. The company’s market capitalization is $515.03 million. Entellus Medical, Inc. has a one year low of $11.47 and a one year high of $22.63.

Entellus Medical (NASDAQ:ENTL) last posted its quarterly earnings data on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.03). Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. The firm had revenue of $22.10 million for the quarter, compared to the consensus estimate of $21.87 million. During the same period in the prior year, the company earned ($0.27) EPS. The company’s revenue for the quarter was up 18.0% compared to the same quarter last year. Analysts predict that Entellus Medical, Inc. will post ($1.61) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Entellus Medical, Inc. (ENTL) VP Sells $40,020.00 in Stock” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/10/09/entellus-medical-inc-entl-vp-sells-40020-00-in-stock.html.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Frontier Capital Management Co. LLC lifted its position in Entellus Medical by 85.0% during the second quarter. Frontier Capital Management Co. LLC now owns 866,370 shares of the medical technology company’s stock worth $14,347,000 after purchasing an additional 397,953 shares during the period. First Light Asset Management LLC lifted its position in Entellus Medical by 25.7% during the second quarter. First Light Asset Management LLC now owns 512,416 shares of the medical technology company’s stock worth $8,486,000 after purchasing an additional 104,919 shares during the period. Vanguard Group Inc. lifted its position in Entellus Medical by 14.2% during the second quarter. Vanguard Group Inc. now owns 485,294 shares of the medical technology company’s stock worth $8,036,000 after purchasing an additional 60,471 shares during the period. Archon Capital Management LLC lifted its position in Entellus Medical by 34.3% during the second quarter. Archon Capital Management LLC now owns 478,820 shares of the medical technology company’s stock worth $7,929,000 after purchasing an additional 122,171 shares during the period. Finally, Kingdon Capital Management L.L.C. lifted its position in Entellus Medical by 79.6% during the first quarter. Kingdon Capital Management L.L.C. now owns 450,371 shares of the medical technology company’s stock worth $6,215,000 after purchasing an additional 199,615 shares during the period. 70.27% of the stock is owned by institutional investors and hedge funds.

A number of research firms have recently commented on ENTL. Zacks Investment Research downgraded shares of Entellus Medical from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. Piper Jaffray Companies reaffirmed a “buy” rating and set a $21.00 price objective on shares of Entellus Medical in a report on Tuesday, August 22nd. Finally, BidaskClub raised shares of Entellus Medical from a “hold” rating to a “buy” rating in a report on Saturday, August 19th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $21.83.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Stock Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related stocks with our FREE daily email newsletter.